CMTA is funding researchers at La Jolla Labs, working with John Svaren, PhD, to develop an ASO treatment that increases MFN1 expression as a potential way to compensate for the damaging effects of MFN2 mutations that cause CMT2A.
Retired nurse Colleen Coogan shares three practices that helped her stop fighting her CMT fatigue and start listening to what her body needs.
See how CMTA-funded research is moving CMT treatments forward in our recap of Day 2 of the 2026 CMTA Patient & Research Summit.